keyword
https://read.qxmd.com/read/26508919/the-influence-of-asian-dust-haze-mist-and-fog-on-hospital-visits-for-airway-diseases
#21
JOURNAL ARTICLE
Jinkyeong Park, Myoung Nam Lim, Yoonki Hong, Woo Jin Kim
BACKGROUND: Asian dust is known to have harmful effects on the respiratory system. Respiratory conditions are also influenced by environmental conditions regardless of the presence of pollutants. The same pollutant can have different effects on the airway when the air is dry compared with when it is humid. We investigated hospital visits for chronic obstructive pulmonary disease (COPD) and asthma in relation to the environmental conditions. METHODS: We conducted a retrospective study using the Korean National Health Insurance Service claims database of patients who visited hospitals in Chuncheon between January 2006 and April 2012...
October 2015: Tuberculosis and Respiratory Diseases
https://read.qxmd.com/read/26501308/coarse-particulate-air-pollution-associated-with-increased-risk-of-hospital-admissions-for-respiratory-diseases-in-a-tropical-city-kaohsiung-taiwan
#22
JOURNAL ARTICLE
Meng-Hsuan Cheng, Hui-Fen Chiu, Chun-Yuh Yang
This study was undertaken to determine whether there was an association between coarse particles (PM₂.₅-₁₀) levels and frequency of hospital admissions for respiratory diseases (RD) in Kaohsiung, Taiwan. Hospital admissions for RD including chronic obstructive pulmonary disease (COPD), asthma, and pneumonia, and ambient air pollution data levels for Kaohsiung were obtained for the period from 2006 to 2010. The relative risk of hospital admissions for RD was estimated using a case-crossover approach, controlling for weather variables, day of the week, seasonality, and long-term time trends...
October 2015: International Journal of Environmental Research and Public Health
https://read.qxmd.com/read/26496331/oscillating-positive-expiratory-pressure-on-respiratory-resistance-in-chronic-obstructive-pulmonary-disease-with-a-small-amount-of-secretion-a-randomized-clinical-trial
#23
RANDOMIZED CONTROLLED TRIAL
Ada Clarice Gastaldi, Paolo Paredi, Anjana Talwar, Sally Meah, Peter J Barnes, Omar S Usmani
This study aims to evaluate the acute effects of an oscillating positive expiratory pressure device (flutter) on airways resistance in patients with chronic obstructive pulmonary disease (COPD).Randomized crossover study: 15 COPD outpatients from Asthma Lab-Royal Brompton Hospital underwent spirometry, impulse oscillometry (IOS) for respiratory resistance (R) and reactance (X), and fraction exhaled nitric oxide (FeNO) measures.Thirty minutes of flutter exercises: a "flutter-sham" procedure was used as a control, and airway responses after a short-acting bronchodilator were also assessed...
October 2015: Medicine (Baltimore)
https://read.qxmd.com/read/26106207/radioaerosol-pulmonary-deposition-using-mesh-and-jet-nebulizers-during-noninvasive-ventilation-in-healthy-subjects
#24
RANDOMIZED CONTROLLED TRIAL
Valdecir C Galindo-Filho, Maria Eveline Ramos, Catarina S F Rattes, Antônio K Barbosa, Daniella C Brandão, Simone Cristina S Brandão, James B Fink, Armèle Dornelas de Andrade
BACKGROUND: In vivo deposition studies of aerosol administration during noninvasive ventilation (NIV) are scarce in the literature. The aim of this study was to compare radioaerosol pulmonary index and radioaerosol mass balance in the different compartments (pulmonary and extrapulmonary) of radio-tagged aerosol administered using vibrating mesh nebulizers and conventional jet nebulizers during NIV. METHODS: This was a crossover clinical trial involving 10 healthy subjects (mean age of 33...
September 2015: Respiratory Care
https://read.qxmd.com/read/26043025/simvastatin-suppresses-airway-il-17-and-upregulates-il-10-in-patients-with-stable-copd
#25
RANDOMIZED CONTROLLED TRIAL
Kittipong Maneechotesuwan, Adisak Wongkajornsilp, Ian M Adcock, Peter J Barnes
BACKGROUND: Statins have immunomodulatory properties that may provide beneficial effects in the treatment of COPD. We investigated whether a statin improves the IL-17/IL-10 imbalance in patients with COPD, as has previously been demonstrated in patients with asthma. METHODS: Thirty patients with stable COPD were recruited to a double-blind, randomized, controlled, crossover trial comparing the effect of simvastatin, 20 mg po daily, with that of a matched placebo on sputum inflammatory markers and airway inflammation...
November 2015: Chest
https://read.qxmd.com/read/25740265/pharmacokinetics-of-qmf149-in-japanese-versus-caucasian-subjects-an-open-label-randomized-phase-i-study
#26
RANDOMIZED CONTROLLED TRIAL
Sayaka Shimada, Soniya Vaidya, Sanjeev Khindri, Natsuka Tashiro, Yi Cheng, Hisanori Hara, Tapan Majumdar, Ralph Woessner, Kenichi Furihata, Kiyoshi Kobayashi
OBJECTIVES: This study aimed to evaluate influence of ethnic factors on the pharmacokinetics of orally inhaled QMF149, a novel combination of an approved longacting β2-agonist, indacaterol (Onbrez® Breezhaler® for COPD), and an approved inhaled corticosteroid, mometasone furoate (MF), (Asmanex® Twisthaler® for asthma), following multiple dose administration of QMF149 (indacaterol acetate/MF) 150/80 μg and 150/320 μg via the Breezhaler® device in healthy Japanese and Caucasian subjects...
May 2015: International Journal of Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/25072896/short-term-effects-of-fine-particulate-air-pollution-on-hospital-admissions-for-respiratory-diseases-a-case-crossover-study-in-a-tropical-city
#27
JOURNAL ARTICLE
Shang-Shyue Tsai, Hui-Fen Chiu, Saou-Hsing Liou, Chun-Yuh Yang
This study was undertaken to determine whether there was a correlation between fine particles (PM2.5) levels and hospital admissions for respiratory diseases in Kaohsiung, Taiwan. Hospital admissions for respiratory diseases including pneumonia, asthma, and chronic obstructive pulmonary disease (COPD) and ambient air pollution data for Kaohsiung were obtained for the period 2006-2010. The relative risk (RR) of hospital admissions for respiratory diseases was estimated using a case-crossover approach, controlling for weather variables, day of the week, seasonality, and chronic time trends...
2014: Journal of Toxicology and Environmental Health. Part A
https://read.qxmd.com/read/25027304/randomized-study-of-the-safety-pharmacokinetics-and-bronchodilatory-efficacy-of-a-proprietary-glycopyrronium-metered-dose-inhaler-in-study-patients-with-chronic-obstructive-pulmonary-disease
#28
RANDOMIZED CONTROLLED TRIAL
Stephen Rennard, Charles Fogarty, Colin Reisner, Carlos Fernandez, Tracy Fischer, Michael Golden, Earl St Rose, Patrick Darken, Gregory Tardie, Chadwick Orevillo
BACKGROUND: Bronchodilator medications are central to the symptomatic management of chronic obstructive pulmonary disease (COPD). Metered-dose inhalers (MDIs) are the most commonly used devices to deliver treatment to patients with COPD and asthma, comprising approximately 70% of bronchodilator prescriptions. Proprietary porous-particle technology permits the formulation of long-acting muscarinic antagonists, long-acting β2-agonists, and a combination of both in hydrofluoroalkane (HFA) MDIs, providing a solution to formulation challenges inherent to the development of HFA MDIs, which have contributed to the development of dry-powder inhalers...
July 16, 2014: BMC Pulmonary Medicine
https://read.qxmd.com/read/24429275/efficacy-and-safety-of-rpl554-a-dual-pde3-and-pde4-inhibitor-in-healthy-volunteers-and-in-patients-with-asthma-or-chronic-obstructive-pulmonary-disease-findings-from-four-clinical-trials
#29
RANDOMIZED CONTROLLED TRIAL
Lui G Franciosi, Zuzana Diamant, Katharine H Banner, Rob Zuiker, Nicoletta Morelli, Ingrid M C Kamerling, Marieke L de Kam, Jacobus Burggraaf, Adam F Cohen, Mario Cazzola, Luigino Calzetta, Dave Singh, Domenico Spina, Michael J A Walker, Clive P Page
BACKGROUND: Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug. We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug. METHODS: Between February, 2009, and January, 2013, we undertook four proof-of-concept clinical trials in the Netherlands, Italy, and the UK...
November 2013: Lancet Respiratory Medicine
https://read.qxmd.com/read/24070494/inhaled-long-acting-%C3%AE-2-agonists-enhance-glucocorticoid-receptor-nuclear-translocation-and-efficacy-in-sputum-macrophages-in-copd
#30
JOURNAL ARTICLE
Rubaiyat Haque, Amir Hakim, Thunicia Moodley, Alfonso Torrego, Sarah Essilfie-Quaye, Elen Jazrawi, Malcolm Johnson, Peter J Barnes, Ian M Adcock, Omar Sharif Usmani
BACKGROUND: Combination inhaled therapy with long-acting β2 agonists (LABAs) and corticosteroids is beneficial in treating asthma and chronic obstructive pulmonary disease (COPD). OBJECTIVE: In asthma, LABAs enhance glucocorticoid receptor (GR) nuclear translocation in the presence of corticosteroids. Whether this biological mechanism occurs in COPD, a relatively corticosteroid-resistant disease, is uncertain. METHODS: Eight patients with mild/moderate COPD participated in a double-blind, placebo-controlled, crossover study and inhaled single doses of fluticasone propionate (FP) 100 μg, FP 500 μg, salmeterol xinafoate (SLM) 50 μg, and combination FP 100 μg + SLM 50 μg...
November 2013: Journal of Allergy and Clinical Immunology
https://read.qxmd.com/read/23688422/airway-responsiveness-to-adenosine-after-a-single-dose-of-fluticasone-propionate-discriminates-asthma-from-copd
#31
RANDOMIZED CONTROLLED TRIAL
Lucia Spicuzza, Vincenza Scuderi, Jaymin B Morjaria, Gaetano Prosperini, Giuseppe Arcidiacono, Massimo Caruso, Caterina Folisi, Giuseppe U Di Maria, Riccardo Polosa
BACKGROUND: Regular treatment with inhaled corticosteroids (ICS) is known to reduce airway hyperresponsiveness (AHR) to adenosine 5'-monophosphate (AMP) in asthma even after a single dose of fluticasone propionate (FP). AIM: To determine whether this rapid protective effect of a single dose of FP is also present in COPD. METHODS: 23 mild asthmatic and 24 COPD subjects with documented AHR to both AMP and methacholine took part in a randomized, double-blind, placebo-controlled, crossover study to measure AHR to inhaled AMP and methacholine 2 h after either 1000 μg FP or matched placebo...
February 2014: Pulmonary Pharmacology & Therapeutics
https://read.qxmd.com/read/23525511/comparison-of-the-systemic-bioavailability-of-mometasone-furoate-after-oral-inhalation-from-a-mometasone-furoate-formoterol-fumarate-metered-dose-inhaler-versus-a-mometasone-furoate-dry-powder-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease
#32
RANDOMIZED CONTROLLED TRIAL
Teddy Kosoglou, James Hubbell, Fengjuan Xuan, David L Cutler, Alan G Meehan, Bhavna Kantesaria, Bret A Wittmer
BACKGROUND: Coadministration of mometasone furoate (MF) and formoterol fumarate (F) produces additive effects for improving symptoms and lung function and reduces exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). The present study assessed the relative systemic exposure to MF and characterized the pharmacokinetics of MF and formoterol in patients with COPD. METHODS: This was a single-center, randomized, open-label, multiple-dose, three-period, three-treatment crossover study...
2013: International Journal of Chronic Obstructive Pulmonary Disease
https://read.qxmd.com/read/23448616/effect-of-ticagrelor-on-pulmonary-function-in-healthy-elderly-volunteers-and-asthma-or-chronic-obstructive-pulmonary-disease-patients
#33
RANDOMIZED CONTROLLED TRIAL
Kathleen Butler, Juan Maya, Renli Teng
BACKGROUND: Ticagrelor is a direct-acting, reversibly binding, oral P2Y12 platelet inhibitor that reduces thrombotic cardiovascular events in patients with acute coronary syndrome. Dyspnea is one of the most commonly reported adverse events associated with ticagrelor. OBJECTIVE: To determine the effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease (COPD) patients. METHODS: Two randomized, double-blind, placebo-controlled, two-way crossover, single-center studies were conducted: 1) healthy elderly volunteers (55-75 years; n = 12); 2) patients with mild asthma (n = 11) or mild-to-moderate COPD (n = 7)...
May 2013: Current Medical Research and Opinion
https://read.qxmd.com/read/23369324/a-short-term-educational-program-improved-physicians-adherence-to-guidelines-for-copd-and-asthma-in-shanghai
#34
JOURNAL ARTICLE
Xiaocong Fang, Shanqun Li, Lei Gao, Naiqing Zhao, Xiangdong Wang, Chunxue Bai
UNLABELLED: BACKGROUND: Chronic pulmonary diseases such as chronic obstructive pulmonary disease (COPD) and asthma exert increasing burden on society while the management of them is far from adequate. The objective of this study is to evaluate adherence to guidelines through a patient study, and then investigate the effects of a short-term quality improvement educational program among clinicians in Shanghai, China. METHODS: A prescription survey was performed in a random sample of 100 COPD and asthma outpatients to assess their pharmacological therapy...
2012: Clinical and Translational Medicine
https://read.qxmd.com/read/23078274/how-air-pollution-influences-clinical-management-of-respiratory-diseases-a-case-crossover-study-in-milan
#35
JOURNAL ARTICLE
Pierachille Santus, Antonio Russo, Enzo Madonini, Luigi Allegra, Francesco Blasi, Stefano Centanni, Antonio Miadonna, Gianfranco Schiraldi, Sandro Amaducci
BACKGROUND: Environmental pollution is a known risk factor for multiple diseases and furthermore increases rate of hospitalisations. We investigated the correlation between emergency room admissions (ERAs) of the general population for respiratory diseases and the environmental pollutant levels in Milan, a metropolis in northern Italy. METHODS: We collected data from 45770 ERAs for respiratory diseases. A time-stratified case-crossover design was used to investigate the association between air pollution levels and ERAs for acute respiratory conditions...
2012: Respiratory Research
https://read.qxmd.com/read/23076649/acute-respiratory-health-effects-of-urban-air-pollutants-in-adults-with-different-patterns-of-underlying-respiratory-disease
#36
MULTICENTER STUDY
A J Mehta, C Schindler, L Perez, N Probst-Hensch, J Schwartz, O Brändl, W Karrer, J M Tschopp, T Rochat, N Künzli
OBJECTIVE: Whether underlying chronic respiratory diseases are susceptible factors for symptomatic episodes, which lead to primary-level care, in association with air pollutant exposures is unknown. We evaluated and compared association lag structures between daily ambient levels of nitrogen dioxide (NO(2)) and total suspended particulates (TSP) and respiratory symptom-related doctor visits in adults with different patterns of underlying chronic respiratory disease. METHODS: In a time-stratified case-crossover analysis nested within a diary panel study, 459 Swiss adult participants with asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD) and healthy participants recorded occurrence of respiratory-symptom related doctor visits (n = 1,048) in one to six four-week intervals over two years...
2012: Swiss Medical Weekly
https://read.qxmd.com/read/23073336/effects-of-tiotropium-on-lung-function-in-severe-asthmatics-with-or-without-emphysematous-changes
#37
JOURNAL ARTICLE
Makoto Yoshida, Takako Nakano, Satoru Fukuyama, Takafumi Matsumoto, Miyuki Eguchi, Atsushi Moriwaki, Shohei Takata, Kentaro Machida, Akiko Kanaya, Koichiro Matsumoto, Yoichi Nakanishi, Hiromasa Inoue
The effects of tiotropium, an inhaled long-acting anti-cholinergic agent, on lung function were investigated in obstructed severe asthmatics with and without emphysematous changes despite maximal recommended treatments with high-dose of inhaled glucocorticoids and inhaled long-acting β(2)-agonists. We conducted a double-blind, placebo-controlled study of an inhaled single-dose of tiotropium in 18 asthmatics with emphysema and 18 without emphysema in a crossover manner. The primary efficacy outcome was the relative change in forced expiratory volume in 1 s (FEV(1)) from baseline to 60 min, and the secondary outcome was a relative change in FEV(1) from baseline to 12 h...
April 2013: Pulmonary Pharmacology & Therapeutics
https://read.qxmd.com/read/22789766/effect-of-once-daily-fluticasone-furoate-vilanterol-on-24-hour-pulmonary-function-in-patients-with-chronic-obstructive-pulmonary-disease-a-randomized-three-way-incomplete-block-crossover-study
#38
RANDOMIZED CONTROLLED TRIAL
Joseph A Boscia, Krishna K Pudi, Michael T Zvarich, Lisa Sanford, Sarah K Siederer, Courtney Crim
BACKGROUND: Available inhaled corticosteroid/long-acting β(2)-agonist combinations for chronic obstructive pulmonary disease (COPD) require twice-daily administration. The combination of fluticasone furoate (FF) and vilanterol (VI) FF/VI is being developed in a novel dry powder inhaler for the treatment of COPD and asthma with the potential for once-daily dosing. Results from Phase II studies have shown clinically and statistically significant improvements over placebo in trough (24-hour postdose) forced expiratory volume in 1 second (FEV(1)) after once-daily dosing with FF or VI (VI concurrently with an inhaled corticosteroid) in asthma and VI in COPD...
August 2012: Clinical Therapeutics
https://read.qxmd.com/read/22531667/pm10-induced-hospital-admissions-for-asthma-and-chronic-obstructive-pulmonary-disease-the-modifying-effect-of-individual-characteristics
#39
JOURNAL ARTICLE
Cristina Canova, Christina Dunster, Frank J Kelly, Cosetta Minelli, Pallav L Shah, Cielito Caneja, Michael K Tumilty, Peter Burney
BACKGROUND: Evidence suggests that oxidative stress is a unifying feature underlying the toxic actions of particulate matter (PM). We have investigated whether individual plasma antioxidant concentrations (uric acid and vitamins C, A, and E) and 10 antioxidant genes modify the response to PM with respect to hospital admissions for chronic obstructive pulmonary disease (COPD) or asthma. METHODS: Using a bidirectional, hospital-based, case-crossover study, 209 patients admitted for asthma or COPD to the Chelsea and Westminster Hospital (London), with 234 admissions, were recruited between May 2008 and July 2010...
July 2012: Epidemiology
https://read.qxmd.com/read/22526864/%C3%AE-2-adrenergic-receptor-haplotype-may-be-associated-with-susceptibility-to-desensitization-to-long-acting-%C3%AE-2-agonists-in-copd-patients
#40
RANDOMIZED CONTROLLED TRIAL
Hideaki Mochizuki, Yuta Nanjo, Eriko Kawate, Mariko Yamazaki, Yasunari Tsuda, Hideki Takahashi
PURPOSE: Τhat β2-adrenergic receptor (β2AR) haplotypes may play a key role in clinical response to β2-agonists and haplotype Cys-19Gly16Gln27 (CysGlyGln) is reported to be associated with desensitization of β2AR to β-agonists in lymphocytes isolated from patients with asthma and septic shock. We sought to determine whether haplotypic variation of the β2AR affects the functional outcomes of long-acting β2-agonist (LABA) treatment for chronic obstructive pulmonary disease (COPD) when used as monotherapy...
August 2012: Lung
keyword
keyword
108464
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.